Sign in to continue:

Wednesday, May 6th, 2026

Cohen & Company Inc. 2026 Q1 10-Q Report Highlights: Financial Results, Segment Performance, and Investment Activities

Cohen & Company Inc. Q1 2026 Financial Results: Key Highlights for Investors

Cohen & Company Inc. (NYSE American: COHN) Reports Q1 2026 Results – Key Takeaways for Investors

Overview

Cohen & Company Inc., a financial services firm listed on the NYSE American under the ticker COHN, has released its quarterly report for the period ended March 31, 2026. The company remains headquartered at Cira Centre, 2929 Arch Street, 17th Floor, Philadelphia, PA, and continues to focus on its core businesses of Capital Markets, Asset Management, and Principal Investing.

Key Shareholder Information

  • Common Stock: The company has authorized 100,000,000 shares of common stock at a par value of \$0.01 per share. As of March 31, 2026, 2,477,655 shares are issued and outstanding, up from 2,130,063 at year-end 2025. This increase may indicate equity compensation, share issuance, or conversion activities, which could affect share value.
  • Preferred Stock: 50,000,000 shares authorized, with 27,413,098 shares issued and outstanding as of March 31, 2026, unchanged from the prior period. The par value remains \$0.001 per share.
  • Trading Information: COHN trades on the NYSE American. No changes to the trading status or exchange listing were noted.

Notable Corporate Structure and Shareholder Rights

  • The company operates with several business segments: Capital Markets, Asset Management, and Principal Investing, each with its own reporting and financial structure.
  • LLC Units Conversion: Units of membership interest in the Operating LLC not held by Cohen & Company Inc. may be redeemed and exchanged into shares of the company on a ten-for-one basis. These units are redeemable for cash (based on a 10-day average price) or at the company’s option, one-tenth of a share per unit. This feature could result in dilution for common shareholders if exercised in large numbers, potentially impacting share price.
  • Voting Rights: Certain classes of preferred stock (e.g., Series C, E, and F) have a ratio of shares to votes (e.g., 10:1), which may further affect control and influence over the company.
  • Restricted Awards: There are significant unvested or restricted awards (589,782 shares as of March 31, 2026, up from 380,008 at year-end 2025), which could result in future dilution.

Balance Sheet and Financial Highlights

  • Segment Reporting: The company reports three operating and reportable segments, which may aid in understanding profitability and risk allocation.
  • Debt and Credit Facilities:
    • The company maintains credit arrangements with minimum tangible net worth and asset capital requirements (\$70 million and \$30 million, respectively, as of March 31, 2026).
    • No line of credit was drawn as of December 31, 2025, indicating financial flexibility.
    • Junior subordinated notes outstanding remain significant, with a combined yield to maturity of 18.88% as of March 31, 2026. Such high yields could indicate elevated risk or market concerns regarding credit quality.
  • Shareholder Equity:
    • The report provides a detailed breakdown of equity components, including preferred stock, common stock, additional paid-in capital, retained earnings, accumulated other comprehensive income, and noncontrolling interests.
  • Geographic Breakdown: The company reports U.S. and Europe as its principal geographic regions.

Potentially Price-Sensitive and Noteworthy Items

  • Increase in Outstanding Common Shares: The notable increase in issued and outstanding common shares (from 2,130,063 to 2,477,655) could suggest dilution, equity compensation, or other capital-raising activities. This could affect earnings per share and investor value.
  • Redemption Rights for LLC Units: The ability of non-controlling interest holders to convert LLC units into common stock on a ten-for-one basis introduces the potential for further dilution.
  • High Yield on Junior Subordinated Notes: The 18.88% yield signals heightened credit risk, which may concern debt and equity investors.
  • Large Amount of Unvested/Restricted Awards: The increase in unvested or restricted stock awards may lead to future dilution and impact share price performance.
  • Segment Structure and Reporting: The company’s focus on three main operating segments (Capital Markets, Asset Management, Principal Investing) may be of interest to investors seeking to analyze operational performance and risk.
  • Compliance and Filing Status: The company confirms it has complied with all filing requirements and is classified as a “Non-accelerated filer” and a “Smaller reporting company,” which may affect regulatory and reporting obligations.

Other Comments

  • No Evidence of Rule 10b5-1 Arrangements: The company indicates that no Rule 10b5-1 or non-Rule 10b5-1 trading arrangements were adopted or terminated during the period, reducing concerns over executive trading activity.
  • All Potentially Dilutive Securities Included: The company states all potentially dilutive securities were included in diluted earnings per share calculations, providing transparency for investors.
  • No New Securities Registered: Only the common stock, par value \$0.01 per share, is registered on the NYSE American.

Conclusion

Shareholders should pay careful attention to: the increase in outstanding shares, the structure and conversion rights of LLC units (potential dilution), the high yield on subordinated notes (credit risk), and the rising number of restricted stock awards (future dilution). These factors could materially affect the share price and warrant close monitoring by investors.

The company’s continued compliance with reporting requirements and stable segment structure provide a foundation for analysis, but the financial leverage and potential for dilution must be considered in any investment decision.


Disclaimer: This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Investors should conduct their own due diligence or consult a financial advisor before making investment decisions. Information was compiled from Cohen & Company Inc.’s Q1 2026 SEC filing and is believed to be accurate as of the date of publication, but no warranty is given as to its completeness or accuracy.


View Cohen & Co Inc. Historical chart here



Citius Oncology Secures $36.5 Million Financing to Accelerate LYMPHIR® Commercialization and Growth

Citius Oncology Secures \$36.5 Million in Financing to Accel...

MarineMax Announces New $100 Million Stock Repurchase Plan Through March 2028

MarineMax Announces New \$100 Million Share Repurchase Plan ...

   Ad

Join Our Investing Seminar

Limited seats available — Reserve your spot today